NBI-1065890
Phase 2Small molecule
Neurocrine BiosciencesNBI-1065890 is one of 9 small molecule programs targeting Tardive Dyskinesia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Tardive Dyskinesia
#DrugCompanyPhaseTrials
1Ingrezza
Neurocrine BiosciencesApproved
Zyprexa
MMODAG GmbH
Approved
Risperdal
WWim Janssens
Approved
Barhemsys
Tibotec Pharmaceuticals, IrelandApproved
Abilify
OtsukaApproved
Reminyl
WWim Janssens
Approved
Austedo
TevaApproved
NBI-1065890
Neurocrine BiosciencesPhase 2
Sarizotan
EMD SeronoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NBI-1065890. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company